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Introduction
In 2009, the WHO declared antibiotic resistance one of the biggest threats to mankind. 1 One answer to the crisis seems simple: to generate new antibiotics. However, it takes 10-15 years from the discovery of a compound to progress through pre-clinical and clinical development before a medicine can be licensed and then marketed. 2 Furthermore, the average expenditure required to research and develop a compound is estimated at $350 million 3 (not including failures, which can increase the cost to $5 billion). 4 This cost could bankrupt a small or mid-size company. Once an antibiotic has been discovered, data must be provided to show a safety profile suitable for human testing. This pre-clinical development phase typically provides animal pharmacokinetic data, toxicity profiles and efficacy against the bacterial target.
Before compounds can be tested in human clinical trials, an institution must apply to the appropriate national or regional drug regulatory authority indicating that, based upon pre-clinical data, the drug is deemed safe to be tested in humans. In the USA, an Investigational New Drug (IND) application from the US FDA must be granted before testing can commence. Similar processes exist for the EU (via the EMA) and in Japan and China. Typically, 17.3% of antimicrobial compounds in pre-clinical development proceed to Phase 1 clinical trials. 2 Once an IND application has been granted, pre-marketing clinical trials are split into three phases (Table 1) .
There is no doubt that the antibiotic pipeline needs revitalization; however, the answer may be not only the development of new drugs, but also re-investigating compounds previously discontinued. Unfortunately, no database exists that records the discovery of compounds and those in pre-clinical and clinical development alongside those that did not become approved drugs, or the reasons for the lack of development or approval. There is an existing database of microbial compounds, but this only provides chemical and physical data on some drugs. 5 This article describes the first publicly accessible free database of antibacterial compounds, AntibioticDB. This includes links to data on discovery, research and clinical trials, compounds awaiting approval from the FDA/EMA and discontinued compounds. AntibioticDB aims to serve as a platform for future research, antibiotic discovery and development.
Methods

Sources of information on antibacterial compounds
Compounds and drugs were identified by reading material from numerous sources including: (i) the ASM Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) or European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference proceedings from 1961 to 2016; (ii) Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, Journal of Medicinal Chemistry and Bioorganic and Medicinal Chemistry Letters; and (iii) Google patent searches (https://patents.google.com) with the search terms 'antibiotic' and 'antibacterial'. Additional names of compounds and drugs were obtained by discussion with key opinion leaders who had worked in the pharmaceutical industry. Once names had been obtained, information on each compound/drug was obtained by additional internet searches, for example on PubMed.
Where available, links to published abstracts are included in AntibioticDB. For abstracts before 2013, the year the compound was first described is indicated. Wherever possible, any compound described in pharmaceutical or biotech company literature or web sites and/or by research institutes and/or universities has also been included. If a compound has been developed by an organization with a web site that details the current status of the compound, this web site is listed. If a compound has been patented, the web address is indicated regardless of whether the patent has expired or not. Information regarding drug patents was primarily obtained through Google's patent search feature. Drugs in clinical trials included in AntibioticDB were not limited to those only under FDA or EMA approval, but also included other drug-monitoring organizations such as, but not limited to, the Pharmaceuticals and Medical Devices Agency, Japan (PMDA). Table 2 shows the definitions of terms used in AntibioticDB. Bracketed compounds in AntibioticDB represent the most promising compounds of a series of analogues. Information on the inferior derivative compounds can often be found in the reference provided.
Limitations of AntibioticDB
The current focus of AntibioticDB is compounds active against Grampositive and/or -negative bacteria; compounds that target Mycobacterium tuberculosis are not currently included. It is intended that AntibioticDB will be continually updated and extended. Individuals and organizations are invited to contribute information subject to peer review by BSAC. AntibioticDB has a short web-based form to facilitate this process.
In contrast to the abstracts presented after 1990, in the earlier years of ICAAC very few of the presented abstracts were uploaded in full to the internet, meaning that available data on some of the compounds is very scarce. In this case, AntibioticDB serves as a platform for interested parties to contact original authors to obtain information directly that cannot be found elsewhere in the literature.
Results
AntibioticDB comprises two types of data: (i) antibacterial compounds in current development and for which data have been published since April 2013 (this information is indicative of the current antibiotic development pipeline); and (ii) compounds described between 1961 and 31 March 2017 that were discontinued at varying stages of development. There are 147 pre-clinical compounds listed currently under research and/or development; 77 have some activity against Gram-negative bacteria. Only six of these compounds state they specifically target MDR Gram-negative infections; examples include NAB-739, a polymyxin derivative (Northern Antibiotics) and FSI-1686, a carbapenem (Merck & Co.). Some companies have focused on creating analogues of pre-existing compounds with a better pharmacological profile than predecessor compounds of the same class. As a result, some novel compounds are being developed that belong to preexisting drug classes. Kibdelomycin, a type II topoisomerase inhibitor (Merck & Co.), targets Clostridium difficile infections and has a low propensity to select resistant bacteria. 6 Nabriva Therapeutics has an ongoing pre-clinical programme investigating extended-spectrum pleuromutilins (ESPs), specifically aimed at Gram-negative bacteria. 7 Data from AntibioticDB demonstrate that as of 31 March 2017 there were 53 compounds in active research and development: 12 in Phase 1, 20 in Phase 2, 19 in Phase 3 and 2 in pre-registration. A few compounds in clinical trials are claimed to display novelty in their field with unique modes of action that currently display no modes of resistance. For instance, brilacidin is a member of a new class modelled on host defence proteins (HDP-mimetics; defensin mimetics). Two antimicrobial peptides are in clinical trials: LTX-109 (Lytixar TM , Lytix Biopharma) and Pexiganan TM (Dipexium Pharmaceuticals); both are topical agents for Gram-positive infections. Radezolid (Melinta Therapeutics, USA) is an oxazolidone currently in Phase 2 that has shown successful results against uncomplicated skin and skin-structure infections (uSSSIs) and community-acquired pneumonia (CAP). There are currently Large, randomized, controlled, multicentre studies in which treatment by the study compound is usually compared with the currently accepted 'gold standard'; success in Phase 3 is much higher than in earlier phases, typically 76%, mostly due to the stringency of previous trials. Phase 3 provides clinical data necessary to file for a new drug application (NDA) potential marketing authorization applicant (MAA); application is usually submitted when there are sufficient data on the safety/pharmacology of the compound; typically 80% of antimicrobial compounds awaiting approval are granted an NDA. 4 Often termed post-marketing surveillance; the compound is formulated as a medicine and has been given full marketing approval; data are usually collected on the safety profile of the drug. Further research can be initiated to test the drug profile in different disease states, for combination therapies, alternative delivery systems and different subject groups if the company chooses to do so. Medicines can be discontinued or withdrawn at this stage if it becomes apparent that the medicine has intolerable adverse effects or is unsuitable for clinical practice.
Review JAC 834 discontinued compounds in AntibioticDB, some of which are available to purchase for research.
Compounds in AntibioticDB
Aminoglycosides (20 in AntibioticDB)
Aminoglycosides are broad-spectrum agents derived from Streptomycetes natural products and contain amino sugar subgroups. They act via inhibition of protein synthesis through binding to the ribosomal 30S subunit. 8 The development of 18 aminoglycosides was discontinued, many due to intolerable levels of toxicity. One example is TS2037 (Meiji Seika Pharma, Japan), a derivative of arbekacin, which showed good in vitro broad-spectrum activity, but was discontinued because of its high levels of nephrotoxicity.
Anthracyclines (three in AntibioticDB)
The anthracycline IT-62-B was reported by Taisho Pharmaceuticals (Japan) as having Gram-positive activity. Consistent with the current use of anthracyclines as anti-tumour chemotherapeutics, Indicates a compound with activity against Gram-negative bacteria that is/was in the process of being developed to target these bacteria; includes compounds with a broad spectrum but that are targeted to these bacteria during their development. 6. Gram-positive activity Indicates a compound with activity against Gram-positive bacteria that is/was in the process of being developed to target these bacteria.
Combination agents
Indicates agents used in combination with other antibiotics or other compounds that enhance antibiotic efficacy of the compound in question.
Low propensity
Criteria for selection of compounds with 'propensity to select resistant mutants' were only applied if data were available showing that bacteria had been exposed to the compound for the purpose of detecting bacterial resistance, or if resistance had been observed during a clinical trial; where no data were available, this parameter was left blank in the database.
Mechanism of action
The site/s of interaction of the compound with the bacterium, e.g. cell wall biosynthesis inhibitor, DNA gyrase inhibitor.
Target bacteria
If a compound has a broad spectrum of activity, comparative details of its efficacy against Gram-positive and Gramnegative organisms are provided.
Current status
Gives information on the compound drug: active research (A) or inactive (I).
Reason antibiotic not developed
Indicates why a compound failed to advance further or was taken off the market. To gather this information, the Springer database AdisInsight was used; Dr Lynn L. Silver, Dr Jared A. Silverman, Dr Ursula Theuretzbacher and Dr Glenn Tillotson provided additional information. Blank fields in this section indicate that the original author, or authors of subsequent pieces of work, gave no reason why a compound may have been dropped, which was often found to be the case for compounds predating 1990.
Citation
Indicates the journal article/conference abstract in which the compound was first described; provided as a web address and/or reference. If more than one source is cited, brackets containing the number refers to the reference from which the information was derived. Where possible the first reference will be the first description of the drug (e.g. ICAAC abstract) and the second will be a publication that gives the broadest overview and/or most information regarding the compound.
Compounds shown in brackets in AntibioticDB represent the most promising compounds discussed in a series of analogues. Information on the other derivative compounds can often be found in the reference provided.
Review this molecule was discontinued as an antibacterial due to its cytotoxicity in humans.
Antibodies (11 in AntibioticDB)
Antibodies are immune effector molecules that identify and begin the cascade leading to eradication of foreign material (including bacteria). This is achieved by opsonization of the target bacteria by cells of the immune system. Attenuation of pathogenic bacteria can be by directly blocking a bacterial component essential to virulence (e.g. adhesins or toxins) through binding of specific monoclonal antibodies. These differ from the mechanisms of action of typical antibiotics, suggesting that cross-resistance is unlikely, making monoclonal antibody therapy an attractive option for treatment of bacterial disease. 10 An example of an indirectly neutralizing antibody in AntibioticDB is Thravixa (Emergent Biosolutions, USA), which targets the Bacillus anthracis toxin, reducing the ability of the bacterium to cause disease. 11 Studies in rabbits and Phase 1 clinical trials indicate that the antibody is well tolerated and decreases mortality rates in the animal model. Further identification of novel, highly conserved bacterial targets for antibody therapy is required to render these technologies a viable therapeutic option.
Antimicrobial peptides (AMPs) (60 in AntibioticDB)
AMPs are naturally occurring peptides, often present in the innate immune system, that demonstrate antibacterial activity, and are evolutionarily conserved with a diverse range of functions. They are not only effective as antibiotics but also demonstrate activity against fungi and viruses. 12 Most AMPs act against bacteria via membrane permeabilization, which is possible due to the AMP's amphipathic structure, allowing them to bind to, and penetrate, bacterial membranes. Unfortunately, most AMPs have toxicity issues, hampering their development into therapeutic drugs. 13 One of the main problems with AMPs derived from human immune effectors is the risk that bacteria may become resistant, thus making the immune system redundant. Creating semi-synthetic AMPs using prediction models can help reduce toxicity and improve efficacy 14 as well as generate variation in the AMP structure. However, due to the poor pharmacokinetics of many AMPs, they have been limited to exploration as topical applications. 15 Of the 60 listed, research into 23 is no longer active. Thirty-seven products are in active pre-clinical development, including agents with activity against both Gram-negative and Gram-positive bacteria. AA-139 (Arenicin), developed by Adenium Biotech, Denmark, is currently in pre-clinical development and shows activity against a variety of Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. NAI-603, developed by NAICONS, Italy and NAI-107 developed by Sentinella Pharmaceuticals, Inc. (previously owned by NAICONS), are both currently in pre-clinical development for MRSA. Two AMPs, Lytixar (LTX-109, by Lytix Biopharma, Norway) and Pexiganan by Dipexium Pharmaceuticals (DPRX) are currently in Phase 2 and 3, respectively, for topical administration.
Defensins are a cationic subgroup of AMPs that play a crucial role in innate bacterial immunity. 16 Due to the defensin's cationic (positive) charge they can bind to negatively charged bacterial membranes, producing pore-like structures and enhancing permeability. Brilacidin (Cellceutix, USA), a defensin-mimetic compound, is currently in clinical trials for a wide range of non-infective clinical indications including ulcerative colitis and mucositis, in addition to Phase 2 clinical trials for acute bacterial skin and skin structure infections (ABSSSIs), results of which demonstrated noninferiority to daptomycin. 17 Cellceutix is investigating brilacidin and similar compounds pre-clinically for the management of Gramnegative and fungal infections.
Bacteriocins are AMPs produced by bacteria to defend against competing prokaryotes. Academia has primarily focused on the lantibiotics, which facilitate their action by inhibiting cell wall biosynthesis leading to membrane instability and cell death. 18 Therapeutic use has been hampered by their narrow spectrum, expense of production and limited tissue distribution. AntibioticDB contains examples of several compounds that could serve as a scaffold for optimization and development into therapeutic drugs. For example, Asahikasei Pharma Corp., Japan, was developing API7444 for the treatment of MRSA and penicillin-resistant Streptococcus pneumoniae. While this compound showed potent activity in vitro, its activity against MRSA in mouse models was markedly lower than that of existing treatments and so the compound was discontinued in 2004. Endolysins are ineffective against Gram-negative bacteria since their outer membrane prevents access to the peptidoglycan wall. 21 A novel approach to circumventing this problem is to combine endolysins with an antimicrobial peptide in order to breach the outer membrane. One example is Art-175 (Laboratory of Gene Technology, KU Leuven, Belgium), which combines an endolysin with a targeting peptide that transports the endolysin through the outer membrane of Gram-negative bacteria. Art-175 demonstrated potent activity against P. aeruginosa, 22 suggesting potential in the development of future therapies.
In addition to the use of therapeutic phage lysins, whole-bacteriophage therapy has long been considered a potential treatment for antimicrobial-resistant infections. While this has gained traction in some parts of the world, further development is required, especially with the potential for bacteria to develop phage resistance. Of the 98 cephalosporins listed in AntibioticDB only 4 remain in active development. Cephalosporins are semi-synthetic agents based on the natural product produced by Cephalosporium acremonium. Two of the four cephalosporins listed are currently in pre-clinical development. The fate of one of these products is, however, unclear; CB-027 was in the Cubist Pharmaceuticals programme and had demonstrated broad-spectrum activity against several drug-resistant strains including MRSA, P. aeruginosa and K. pneumoniae. 25 Following the takeover of Cubist by Merck no evidence can be found that development of this product is continuing. Two further cephalosporin-containing products, cefiderocol (a siderophore cephalosporin) and the combination ceftaroline/avibactam, are currently in Phase 3. Currently there is only one licensed monobactam in clinical use, aztreonam. A combination product of aztreonam/avibactam is currently in active development in Phase 2.
Two hundred and three b-lactams (including combination products) have been identified that are no longer the focus of active research and development. These include 43 carbapenems, 98 cephalosporins, 15 monobactams and 14 penicillins.
Efflux inhibitors (13 in AntibioticDB)
Efflux pumps are transmembrane proteins that can extrude diverse substrates, and constitute one of the most common mechanisms underlying intrinsic drug resistance; 26 inhibiting their activity increases bacterial susceptibility to the compounds extruded. MBX 2319 (Microbiotix Inc., USA) a pyranopyridine compound in pre-clinical studies, inhibits the action of the E. coli AcrB multidrug resistance efflux pump. AcrB can extrude a wide array of antibiotics, including chloramphenicol, fluoroquinolones and b-lactams. Use of inhibitors should restore activity to these drugs. Optimization of the molecular scaffolds of these inhibitors for enhanced efficacy and species specificity is under active research.
Development has stopped for the 11 remaining compounds. One, MC-04124, was only discontinued following the closure of Essential Therapeutics, who were developing several efflux inhibitors. Molecules such as these may make good candidates for continued development.
Fab inhibitors (12 in AntibioticDB)
Bacterial fatty acid synthesis (FAS-II) is maintained by a series of mono-functional enzymes that make up the FAS-II pathway. FabI or enoyl-ACP reductase is a key enzyme in the final steps and is conserved throughout most bacterial species. There are eight FabI inhibitors undergoing investigation, with four currently in clinical trials. [27] [28] [29] Debio1450, Debio1452 (Group, Switzerland) and CG-400549 (CrystalGenomics, South Korea) are currently in Phase 2 and being developed for the treatment of ABSSSI. FAB001/ MUT056399 (Fab Pharmaceuticals, India) is a narrow-spectrum FabI inhibitor being developed against MRSA. 27 The four FabI inhibitors currently in pre-clinical development are mostly aimed at Gram-positive bacterial infections, with the exception of PT52 and PT68 (diphenyl ethers) (Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA), which has demonstrated activity against the Gram-negative bacteria Burkholderia pseudomallei.
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FtsZ inhibitors/cell division inhibitors (two in AntibioticDB)
FtsZ is the earliest protein involved in bacterial cytokinesis; its closest homologue in eukaryotic cells is tubulin. There is interest in utilizing FtsZ and other crucial proteins in the bacterial cell division pathway as potential targets. 31 AntibioticDB contains two FtsZ inhibitors, TXA-709 and PC190723, both in pre-clinical development with Taxis Pharmaceuticals Incorporated.
Glycopeptides (including lipoglycopeptides) (29 in AntibioticDB)
Glycopeptides are glycosylated non-ribosomal peptides, comprising both natural and semi-synthetic products, showing activity against Gram-positive bacteria. They bind to a fragment of the outer peptidoglycan layer, D-alanyl-D-alanine, causing inhibition of transglycosylation and transpeptidation, disrupting cell wall synthesis and leading to cell lysis and death. Due to poor permeability and active efflux, glycopeptides have limited activity against Gram-negative bacteria. We include lipoglycopeptides, which are semisynthetic compounds produced through the addition of a lipophilic side chain to the glycopeptide base. Currently there is one agent in pre-clinical development and three in clinical development. In addition, telavancin, dalbavancin and oritavancin have recently received marketing approval. Ramoplanin (Nanotherapeutics, USA) and TD-1607 are currently in Phase 2 and 1, respectively. TD-1607, a glycopeptide-cephalosporin hybrid, is being tested in the management of ABSSSI and ramoplanin is being tested for the treatment of C. difficile. 
Lincosamides (three in AntibioticDB)
Lincosamides inhibit protein synthesis by affecting the assembly of the 30S ribosomal complex. 33 AntibioticDB contains three Review lincomycin analogues and derivatives, with very little academic pursuit beyond discovery. Most of these compounds had adverse toxicological effects in humans, although these were not directly cited as the reason for discontinuing research. Examples include rancomycin 1 and 2, 34 which showed potent broad-spectrum activity, but were discontinued at the preclinical stage owing to toxicity.
Lipopeptides (seven in AntibioticDB)
With the discovery of daptomycin (1986), lipopeptides represent the latest antibiotic class to be approved. They consist of linear or cyclic peptides with a fatty acid group covalently linked to the N-terminus. It is thought that they bind to the bacterial cytoplasmic membrane and aggregate. One lipopeptide, surotomycin (Cubist), was in Phase 3, testing its use against C. difficile-associated diarrhoea; however, the programme stopped following acquisition of Cubist by Merck.
LptD/imp inhibitor (one in AntibioticDB)
Murepavadin (POL7080; Polyphor, Switzerland) is currently in Phase 2. It is a protein epitope mimetic LptD inhibitor being developed for the treatment of P. aeruginosa ventilator-associated bacterial pneumonia, lower respiratory tract infections and bronchiectasis. 35 
Macrolides and macrocycles (59 in AntibioticDB)
These agents are based on naturally occurring polyketides, produced by bacteria such as Micromonospora. 36 The macrolide ring gives the compounds their antibacterial functionality and allows reversible binding to the 50S ribosomal subunit. Three macrolides are currently under active investigation. Solithromycin (Cempra Inc.) has completed Phase 3 for CAP; 37 however, its NDA to the US FDA was rejected in December 2016. Before a re-application can be made the FDA requires further clinical safety information and assurances on the manufacturing facility. A second macrolide, nafithromycin (Wockhardt), will shortly be entering Fifty-six macrolides in AntibioticDB were discontinued (24 categorized as ketolides and 4 azalides), many due to adverse toxic effects in humans or inferior activity to similar, already marketed compounds. Several macrolides were also discontinued due to poor stability in vivo. One example is difficidin (Merck & Co., USA), which, despite showing broad-spectrum activity against aerobic and anaerobic bacteria, was unstable at differing pHs and easily oxidized. This drug showed little activity in a mouse model when administered subcutaneously, but was highly effective when administered through intraperitoneal injection, suggesting that metabolism prevented it from reaching the infection site.
Moenomycins (one in AntibioticDB)
Moenomycins act through direct inhibition of peptidoglycan glycosyltransferases, which are crucial in the last stages of bacterial cell wall synthesis. Research into therapeutic use has been limited due to suboptimal pharmacokinetics, but they represent an attractive scaffold for antibiotic discovery and development. They have recently been shown to be active against MDR Helicobacter pylori.
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Nanoparticles (three in AntibioticDB)
Nanoparticles are between 0.1 and 100 nm; their larger surface area to volume ratio gives them unique properties that can be manipulated to target specific bacterial components via novel mechanisms. In 2011 IBM developed 'ninja particles', which were biodegradable nanoparticles that could target MRSA, and act through a similar mechanism as some immune effectors. These ninja particles target the membrane and cause instability, resulting in lysis. There was also a low propensity to select for resistance. 39 It is well documented that metal alloys have antibacterial properties, 40 and two nanoparticles derived from heavy metals are in pre-clinical development for the treatment of infectious disease, including both silver (nano-Ag) and gold (nano-Au) nanoparticles. Nano-Ag's antimicrobial action is mediated by its binding to the bacterial cell membrane, causing dissipation of the proton motive force and membrane instability. 41 Gold nanoparticles appear to have a more diverse mechanism of action; they have been shown to inhibit the tRNA-binding ribosomal subunit and also to inhibit the action of ATP synthase, having a deleterious effect on bacterial metabolism. 42 Gold nanoparticles can also increase chemotaxis and have subsequent potential to be used in drug-delivery systems. 43 An issue with nanoparticles can be their efficacy in the presence of serum, as serum-protein interactions dissipate nanoparticle activity. Gnanadhas et al. 44 have demonstrated that by citrate-capping silver nanoparticles their interaction with serum proteins could be reduced. This reduction also correlated with a higher cell uptake of free nanoparticles, thereby increasing efficacy and antibacterial activity.
Nitrofurans (two in AntibioticDB)
Nitrofurantoin and furazolidone are currently the only nitrofurans licensed for therapeutic use. Recent studies have shown that nitrofurantoin may be a candidate for revival in the treatment of ESBLproducing E. coli lower UTIs, 45 implying that nitrofurans may be a good base for future redevelopment for treatment of susceptible organisms resistant to first-line antibiotics. One example from AntibioticDB is AS17665, which was discontinued by Abbott Laboratories in 1962. While the exact reason for discontinuation is unclear, the antibiotic was shown to be primarily active against tumours, and hence toxicity is a possible concern. Despite this, the compound was shown to be active against S. aureus, Streptococcus pyogenes, E. coli and Salmonella Typhimurium.
Oxazolidinones (80 in AntibioticDB)
Oxazolidinones (e.g. linezolid) display antibacterial activity against Gram-positive bacteria, but have poor anti-Gram-negative efficacy. Their mechanism is via inhibition of protein synthesis through binding to the P-site of the ribosomal 50S subunit. Currently, four out of the six active oxazolidinone compounds listed in the AntibioticDB are in clinical development. MRX-II (MicuRx Pharmaceuticals, USA) is one of two listed oxazolidinones in pre-clinical development; 46, 47 Review JAC however, any information concerning its development has not been updated since 2012, possibly indicating that it has been dropped for further research. Three oxazolidinones are currently in clinical trials, including MRX-I (MicuRx Pharmaceuticals, USA) in Phase 3 studies for the treatment of skin and soft tissue infections. The remaining two compounds, radezolid and LCB01 0371, are in Phase 2. Radezolid (Melinta Therapeutics, USA) has demonstrated activity against Gram-negative infections and only for Haemophilus influenzae.
48 LCB01 0371 (LegoChem Biosciences, South Korea) is under investigation for the treatment of Gram-positive infections.
Development of 74 oxazolidinones in AntibioticDB has ceased. One, PNU100592 (Pharmacia Corp., USA) was being developed for the treatment of MRSA. This molecule was discontinued due to its inferior activity when compared with linezolid. Many other oxazolidinones were discontinued due to high levels of toxicity. Utilization of this molecular scaffold to reduce toxicity may represent an avenue for the development of novel protein synthesis inhibitors with reduced propensity to select for resistance. Interestingly, when combined with quinolones, the combination includes Gramnegative bacteria in the spectrum of activity. 49 
Pleuromutilins (10 in AntibioticDB)
Pleuromutilins inhibit the 50S ribosomal subunit; retapamulin was approved for human use in 2007, 50 but it has been difficult to develop compounds for systemic use, 50 mainly due to difficult peptide chemistry. Nabriva Therapeutics, Austria, has five candidate compounds in research and development, with one, lefamulin (BC 3781), progressed to Phase 3. Lefamulin is under development for the treatment of ABSSSI, community-acquired bacterial pneumonia and hospital-acquired bacterial pneumonia/ventilatorassociated bacterial pneumonia. 51, 52 Polymyxins (two, and one polymyxin analogue, in AntibioticDB)
Polymyxins are produced by non-ribosomal peptide synthetases in Gram-positive soil bacteria such as Paenibacillus polymyxa. 53 They have selective activity against Gram-negative bacteria, targeting the lipid A component of the outer membrane. 54 Currently, the only polymyxin in clinical use is polymyxin E (colistin), but, due to high incidence of nephrotoxicity, 55 colistin is administered as an agent of last resort against infections by MDR bacteria, such as A. baumannii. The two polymyxins in pre-clinical development and listed in AntibioticDB are NAB-739 and CA-824, which are being developed by Northern Antibiotics (Finland) and Cantab Antiinfectives, respectively.
Quinolones, fluoroquinolones and other topoisomerase inhibitors (146 in AntibioticDB)
The targets for topoisomerase inhibitors in bacteria are DNA gyrase and DNA topoisomerase IV, which are enzymes that regulate bacterial DNA supercoiling and relaxation. 56 There are currently five fluoroquinolones in AntibioticDB undergoing active research and development, four are in clinical studies. Following two successful Phase 3 studies, known as PROCEED, an NDA for delafloxacin (Melinta Therapeutics, USA and Abbott) was submitted in October 2016 for the treatment of gonococcal, skin and soft tissue infections. Zabofloxacin (Dong Wha Pharmaceuticals, South Korea) is in Phase 3 for the treatment of community-acquired bacterial pneumonia and quinolone-non-susceptible gonorrhoea. Finafloxacin (MerLion Pharmaceuticals, Germany) has been licensed topically for the treatment of otitis externa. An oral formulation continues through Phase 2 clinical studies for the management of urinary tract, intra-abdominal and skin and soft tissue infections. Nemonoxacin (TaiGen Biotechnology Co., Taiwan), a nonfluorinated quinolone, is currently in Phase 3 and has promising broad-spectrum activity targeting a variety of infections including vancomycin-non-susceptible MRSA. 57 There are 114 discontinued quinolones and fluoroquinolones documented in AntibioticDB. Research and development into many of these agents was discontinued due to toxicity, although some agents were discontinued due to financial constraints. MCB 3382, a fluoroquinolone-oxalidinone hybrid, was in development by Morphachem AG before the company merged with Biovertis AG, leading to the discontinuation of their antibacterial research programme.
Sideromycins and siderophore antibiotics (eight in AntibioticDB)
Siderophores are iron chelators, which can be exploited in a number of therapeutic processes. 58 Sideromycins are antibiotic moieties covalently linked to siderophores, allowing their selective uptake into the bacterium via the native iron transport systems. 59 This feature is useful in the context of Gram-negative bacteria, in which the outer membrane forms a barrier to drug entry, and the concentrations of some antibiotics required for entry into the cell can become toxic to humans. One such example is cefiderocol, a siderophore cephalosporin, which forms a chelation complex in the presence of iron. Cefiderocol (Shionogi, Japan) has recently completed Phase 3 for MDR Gram-negative infections.
HKI 9924109 (Basilea Pharmaceutica AG, Switzerland) is an ampicillin adduct linked to a synthetic siderophore. This compound was discontinued at the preclinical stage due to its inability, even at high concentrations, to inhibit the growth of non-fermenting Gram-negative bacteria. 60 Despite the shortcomings of some siderophore-antibiotic conjugates, they remain a useful tool for targeted therapeutics. 61 For example, Wencewicz and Miller 62 have reported a siderophore-carbacephalosporin conjugate that selectively targets A. baumannii.
Streptogramins (five in AntibioticDB)
Streptogramins are produced by several Streptomyces species and are structurally unique, having similar mechanisms of action to macrolides and lincosamides, and therefore cross-resistance is possible by target modification, thus limiting therapeutic use. 63 Examples are pristinamycin 1 and 2, which are produced by Streptomyces pristinaespiralis. There are no streptogramins in active research and development listed in AntibioticDB.
Streptothricins (one in AntibioticDB)
Streptothricins have broad-spectrum activity against bacteria and fungi; 64 their therapeutic potential has been hampered by toxicity problems, but they have been successfully utilized for the treatment of infectious diseases in crop plants; streptothricin-type antibiotics have been marketed as fungicidal agents in China. 65 One Review streptothricin compound in AntibioticDB is LL-AB 664, which was reported in 1967. 66 New streptothricin-class antibiotics have been isolated and assessed for their antimicrobial potential recently; some of these display potent activity against a variety of bacteria, particularly M. tuberculosis. 67, 68 If the problem of resistance to these compounds and toxicity in humans can be overcome, they may represent a new avenue for antibiotic development. There are no streptothricins in active research and development listed in AntibioticDB.
Sulphonamides (two in AntibioticDB)
Sulphonamides are synthetic compounds based on the industrial dye sulfachrysoidine; 69 they are analogues of p-aminobenzoic acid (PABA) and inhibit folic acid biosynthesis via competitive inhibition of the enzyme dihydropteroate synthetase. 70, 71 This competitive inhibition is bacteriostatic, disrupting DNA synthesis and bacterial growth. ABEPI 1 and 2 are currently in pre-clinical development. 72 Some antibiotics can act as efflux inhibitors and ABEPI 1 and 2 have been shown to inhibit the efflux activity of the nosocomial bacterium A. baumannii, which allows increased accumulation of the antibiotic minocycline, and subsequent susceptibility to the drug.
Tetracyclines (10 in AntibioticDB)
Tetracyclines are broad-spectrum cyclic antibiotics classified into two types: tetracyclines that bind to the amino-acyl-tRNA acceptor site of the mRNA ribosomal complex, causing disruption of protein synthesis, and those that demonstrate antibacterial activity via cytotoxic perturbation of the cytoplasmic membrane. 73 Out of the four tetracyclines in active development listed in AntibioticDB, two are in pre-clinical development, both by Tetraphase Pharmaceuticals, USA, and two are in Phase 3. The two Phase 3 compounds are omadacycline and eravacycline. Eravacycline (Tetraphase Pharmaceuticals, USA) has received mixed results from the Phase 3 IGNITE studies. In IGNITE1, eravacycline demonstrated non-inferiority to ertapenem in the management of complicated intra-abdominal infections. In IGNITE2, eravacycline showed inferiority to levofloxacin in the treatment of complicated UTIs. 74 The IGNITE2 study protocol authorized intravenous-to-oral switch and further data analysis has suggested participants receiving solely eravacycline intravenously had a more favourable outcome. As a consequence, there is a suggestion that poor clinical outcomes were observed due to problems with the oral eravacycline formulations rather than with the parent compound; two further Phase 3 studies (IGNITE3 and IGNITE4) indicated noninferiority to meropenem in patients with polymicrobial infections. These were included in the recent NDA.
Omadacycline is a semi-synthetic tetracycline being developed by Paratek Pharmaceuticals, technically classed as a novel aminomethylcycline, the first in its class. 75 The newer tetracyclines appear to avoid active efflux by bacteria and are effective against typical tetracycline-resistant bacteria. The mechanism underlying this phenomenon is unknown. 75 AntibioticDB contains four cyclic tetracyclines that have been discontinued for development as antibacterials.
Miscellaneous molecules (121 in AntibioticDB)
A multitude of molecules that do not fit into pre-defined classes of compounds and inhibiting various bacterial functions have been reported to display antibiotic activity. The differences in the structures of these compounds and the commonly used therapeutic classes may provide avenues to identify novel molecular scaffolds, less prone to degradation by bacterial resistance determinants. While this may not be an option in cases where resistance has been acquired by target modification, this remains a resource to bring novelty to the antibiotic research pipeline. Some agents may fit within a class but were not described as such when first reported.
Reasons for discontinuing compounds
Few compounds in the development pipeline become drug candidates and even fewer are approved for clinical use. From analysis of the discontinued compounds, most were discontinued in preclinical research (Figure 1 ). This is as expected, due in part to the large numbers of analogues that are often discarded for inferior activity. There are many factors to be considered before submission of an IND application relating to a promising drug candidate. These include: in vitro and in vivo activity (compounds should have non-inferior activity to other compounds and existing drugs); levels of toxicity; pharmacokinetic profile (e.g. bioavailability, half-life); cross-resistance to other antibiotics or resistance development; and commercial reasons. In reality, few agents reach the stage where all these data are available, as discovery of a key impeding factor, e.g. high toxicity, may preclude any further research and development. The cited reasons for discontinuation of a particular drug given in AntibioticDB are depicted in Figure 2 . As a result of the lack of further pursuit when a compound's poor potential is identified, very few reasons for discontinuation have been published.
Thirty-eight compounds are listed in AntibioticDB where evidence for discontinuation of research was identified as 'due to commercial reasons', company acquisition or the 'financial circumstances of the developing company'. Examples include the Review JAC Genaera 'Magainin program' (company shut down), Essential Therapeutics (bankruptcy) and the Cubist pipeline (acquired by Merck). In these cases, the rights to company assets can be purchased. However, for many early-stage compounds there may not have been a sufficient incentive for these compounds to be purchased. Therefore, it is possible that certain compounds were overlooked or in too early a stage of development, and that these have the potential to be taken to market without optimization or be used as intermediates for further analysis and development.
In the last 15 years many large pharmaceutical companies (including AstraZeneca, Bristol Myers Squibb, Eli Lilly and Wyeth) discontinued antibiotic research because their pipelines had no viable compounds and/or because of economic factors. To identify novel compounds, European and American researchers and companies turned to target-based discovery to identify agents with novel modes of action, whilst Japan tended towards finding derivatives of existing, successful compounds such as fluoroquinolones and b-lactams. In using target-based discovery, researchers encountered many issues with entry of the antibiotics into bacterial cells. The timeline for antibiotic discovery is illustrated in Figure 3 .
Of those agents with a documented reason for termination of development, 50% were discontinued due to toxicity. Many compounds were also discarded where research revealed resistance, unfavourable pharmacokinetics or poor potency. Interestingly, following investigation beyond the published literature from the developer, some compounds were discontinued for 'circumstantial reasons', suggesting that this was not due to unfavourable properties of the compound. One example of this is the compound JNJ-17155437, a ketolide antibiotic reported by Johnson and Johnson. Research and development into this compound was discontinued around about the time that questions were raised around another ketolide antibiotic being developed by the company called telithromycin (Ketek). This drug was approved by the FDA and said to be one of the first compounds of its type to circumvent antimicrobial resistance. 76 In the year following initial approval, several deaths were reported due to liver failure in people treated with telithromycin for CAP. The suboptimal safety profile of this drug and the structurally related JNJ-17155437 may have been the reason for discontinuation of the compound.
Discussion
AntibioticDB was assembled with the intention of generating a platform to facilitate researchers from academic or industry backgrounds to potentially research and develop previously discontinued compounds into new antibacterial drugs. Additionally, it is an accessible source of information to determine the progress of compounds currently in development. While there are databases and publications 5, [77] [78] [79] describing the properties of compounds and their status, including the Springer-AdisInsight and Thomson Reuter databases, these are not widely accessible and some are only available on a paid subscription basis. Furthermore, AntibioticDB includes antibacterial compounds no longer in active development, and indicates, where possible, the reasons why development was discontinued. To identify the latter, the published literature, company web sites and other databases were interrogated and individuals with extensive knowledge were interviewed. It should be noted that for many of the compounds there is little available information as they were discontinued in early pre-clinical development and there was no publicly available information.
Several discontinued antibiotic classes and compounds have been revisited to investigate whether there is any merit in developing them for medical use. For instance, in the 1980s daptomycin (LY 146032) was under development by Eli Lilly and Co.; however, in clinical trials musculo-skeletal damage was shown, and so development of the compound was discontinued. In 1997, Cubist Pharmaceuticals acquired the rights to this drug, and after changing the dosing to intravenous administration once daily daptomycin was found to be safe. It was approved by the FDA and marketed in 2003. 80 Secondly, pleuromutilins such as tiamulin have been previously used in veterinary medicine, but there is now the prospect of developing them as therapies for humans. GSK developed retapamulin (Altabax) and currently Nabriva is developing a further three compounds, 81 including lefamulin, which is a candidate for treatment of CAP. A third drug candidate is iclaprim. In 2009, the US FDA rejected Arpida's application on the grounds of incomplete data to demonstrate efficacy. In April 2015, the FDA accepted the proposal of two further Phase 3 trials by Motif Bio, who gained the rights to the drug and plan to continue its development. 82 These examples indicate that there can be merit in reinvestigating discontinued antibiotics for future development, and AntibioticDB will provide a platform to facilitate this. There is a possibility that with the progression of synthetic chemistry and other areas of science, cross-disciplinary approaches may be able to optimize some old compounds to remove unfavourable characteristics and make them more useful in future. 83 For these agents to be developed there will need to be a financial incentive.
There is also the need to consider the target patient of new antibiotics. Some compounds were discontinued due to toxicity; however, there are certain compounds, e.g. colistin, that despite presenting toxicity issues could progress further through the drug Review development pipeline. However, with the understanding of antimicrobial resistance, it is probable that many new antibiotics will not be widely used. Many will be kept as reserve agents for compassionate designation usage, i.e. usage in mitigating circumstances, where few other therapeutic options are available; this means that the regulatory authorities may allow companies to provide experimental drugs to people outside of clinical trials. Whilst reinvestigating discontinued compounds is a possibility, there are some complications. For instance, the expertise in synthesizing certain compounds or their documentation may no longer be available. This is likely for those companies that have ceased their research in this area or become bankrupt. In these cases, many derivatives may have been synthesized from a promising parental compound that demonstrated toxicity or other unfavourable properties. If the information about these derivatives has been lost, reinvestment is high risk, which highlights the importance of an open-access approach to pre-clinical and clinical development of therapeutic drugs. Another complication is that some discontinued compounds may not have been patented as a drug but as an intermediate. If the patent is still valid another organization synthesizing derivatives may infringe the patent. Finally, a company investigating old compounds will, in order to receive regulatory approval, ultimately need to be able to ensure a steady supply of drug.
While the cases of daptomycin and the pleuromutilins show that 'reviving' old antibiotics is possible and can be successful, it must be considered whether this is a viable path of antibiotic research and development for other discontinued compounds. It is important to note that the currently prevalent bacteria have evolved and disseminated because of selection by antibiotics in current clinical use. Therefore, further development of old and/or compounds of the same class may not be productive as resistance mechanisms active against these agents may already be widely disseminated. Many of the discontinued compounds in AntibioticDB will not have been tested against current clinical isolates, suggesting a potential difference in efficacy from when they were first screened. Nonetheless, compounds that demonstrate a novel mode of action may evade current resistance issues and thus could be clinically useful. This was the case for daptomycin and the pleuromutilins.
The UK Review on Antimicrobial Resistance has questioned the sustainability of the current research and development pipeline for antibiotic development 2 and indicated that for a sustainable future of antibiotic development 15 new antibacterials need to be developed every 10 years. The Review on Antimicrobial Resistance also noted that novelty is a direct issue for today's antibiotic development, with no new antibiotic drug classes having being developed in the past 30 years (since the lipopeptide daptomycin in 1986). Currently there are 152 active pre-clinical compounds listed in the AntibioticDB. The attrition rate in drug development is well known and based on data provided by the Review on Antimicrobial Resistance on success rates it is possible that three may be approved for human use by 2025. 2 This demonstrates a possible gap of 12 licensable compounds over 10 years. Data from the Review on Antimicrobial Resistance suggests the number of preclinical compounds that require testing in order to generate 
AnƟbodies
AnƟbodies are not a class of anƟbioƟcs but they are able to target bacteria through opsonizaƟon, or to neutralize toxins produced by the pathogen. Another approach is conjugaƟon of anƟbodies to anƟbioƟcs.
Streptogramins
Streptogramin B (shown)
NanoparƟcles Alloy metal parƟcles demonstrate anƟbacterial properƟes are now in development for medical usage. Mechanisms are diverse including cell membrane destabilizers or protein synthesis inhibitors. Academia has an important part to play in the fight against antimicrobial-resistant infections, with the need for innovation in the field and subsequent development of antibiotics with novel mechanisms of action at its greatest. This alone, however, is not enough, and only with collaboration between academia, smalland medium-sized enterprises, big pharma, funding bodies and governments can this goal be achieved. AntibioticDB, described herein, provides a valuable tool for anyone involved with antibiotic discovery, research and development. By providing a history of compounds that have been discontinued with the current status of antibiotic discovery, research and development (including preclinical development), AntibioticDB will enable academia and industry alike to explore previously discontinued antibiotics for the treatment of the drug-resistant infections we are faced with today. AntibioticDB is an interactive database; therefore, we call upon all involved in this field, be it pharmaceutical companies, university groups or individuals, to help to continue to populate AntibioticDB. generated Figures 1 and 2 and contributed text for the manuscript. A. J. checked all entries in the database were correct as of March 2017. A. M. supervised R. L., generated the references and contributed to the writing of the manuscript.
